University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
143 articles with University of Texas MD Anderson Cancer Center
Research shows deadly tumors may be vulnerable to drugs that block their energy supply
Preclinical research finds new approach to treating aggressive cancer unresponsive to immunotherapy alone
Immunotherapy combination generates responses against castration-resistant metastatic prostate cancer
Two checkpoint inhibitors provide early encouraging results for immunologically cold disease
Preclinical study identifies vulnerability in orphan cancers with SMARCB1 mutations, spurs launch of Phase II clinical trial
Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma (GBM) progression by shutting down immune surveillance, indicating a potential new area of therapeutic investigation.
MD Anderson Cancer Center and Dragonfly Therapeutics announce strategic collaboration to take new immunotherapy candidates into clinical trials
The University of Texas MD Anderson Cancer Centerand Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly’s TriNKET™ (tri-specific natural killer cell engager therapy) immunotherapy drug candidates to patients in clinical trials beginning in 2019.
Comparison of pancreatic and melanoma tumors highlights importance of stroma
John Mendelsohn, M.D., president emeritus of The University of Texas MD Anderson Cancer Center and an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of cancer therapy, died Jan. 7 at his home in Houston.
MD Anderson Cancer Center and Nanobiotix announce a large-scale, comprehensive clinical collaboration on NBTXR3
Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types
MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors
The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.
Ascentage Pharma and MD Anderson Cancer Center Announce Strategic Alliance in Cancer Drug Development
Five-year collaboration aims to accelerate clinical development of select novel apoptosis-targeted and tyrosine kinase inhibitor product candidates
Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer.
Tvardi Therapeutics Inc. (“Tvardi”), a clinical-stage private biopharmaceutical company focused on the development of STAT3 inhibitors, announced today the completion of a $9 million Series A financing round.
First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain
In the ongoing challenge to combat the almost always deadly brain cancers, namely Glioblastoma and melanoma metastasized to the brain, the pharmaceutical company Moleculin Biotech, Inc., (Nasdaq: MBRX) has initiated a Phase 1 clinical trial of a new first-in-class cancer drug candidate.
The death of Sen. John McCain helped raise awareness about the plight of brain tumor patients and the lack of movement on developing new therapies for this disease over the past several years. But now, Houston-based Moleculin Biotech has launched a clinical trial that could be a game-changer if a...
Genprex Amends Options to License Additional Cancer Fighting Technologies from the University of Texas MD Anderson Cancer Center
Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to extend the terms of two option agreements between Genprex and MD Anderson
The University of Texas MD Anderson Cancer Center today was awarded $30 million to support research, core facilities, recruitment and prevention efforts from the Cancer Prevention and Research Institute of Texas (CPRIT).
According to the National Cancer Institute (NCI), pancreatic cancer is relatively rare, with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases. But each year, 44,330 Americans die from the disease, or about 7.3 percent of cancer deaths.
Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.
Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer
Genprex, Inc. announced that it has amended its agreement with The University of Texas MD Anderson Cancer Center to resume patient enrollment in its Phase I/II clinical trial evaluating the combination of the company’s investigational drug Oncoprex™ and erlotinib (Tarceva®)